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Pfizer, the manufacturer and distributor of the well-known drug Viagra had to take down its publicity on the Dutch 
website www.erectieplein.nl. On this website, sponsored by Pfizer, visitors could anonymously find information on 
erection difficulties and the different remedies and products available on the market. Furthermore, it was possible 
to order and obtain Viagra via links to an online doctor and internet pharmacy. As in other Member States of the 
European Union, advertising for drugs, in particular when they are only available on prescription, is subject to a 
rigorous and restrictive regulatory regime. For this reason the key question the Dutch Commission for 
Pharmaceutical Advertising had to answer was whether the Viagra related messages were objective public 
information or publicity.  
Since European law defines advertising in a very broad manner, the distinction between general information and 
commercials is sometimes very difficult to make. Article 1 of Directive 92/28/EC states that advertising of 
medicinal products shall include any form of door-to-door information, canvassing activity or inducement designed 
to promote the prescription, supply, sale or consumption of medicinal products. Furthermore and with some 
limited exceptions, e.g., corporate websites and press coverage, the Directive on electronic commerce also 
defines electronic commercial communications broadly. Article 2 of the latter Directive states that commercial 
communication means any form of communication designed to promote, directly or indirectly, the goods, services 
or image of a company, organisation or person pursuing a commercial, industrial or craft activity or exercising a 
regulated profession. For this reason, a website where a certain product, e.g., Viagra, or its image is promoted, 
can be considered a commercial communication.  
The Commission for Pharmaceutical Advertising held that the website www.erectieplein.nl had to be considered 
commercial information. In contrast to alternative products, the image of Viagra – and thus the product Viagra – 
was more than present. In addition, the statements made were not always neutral, nor merely informative. 
Furthermore, it was stressed that the links to the online e-doctor and internet pharmacy only referred to Pfizer’s 
Viagra product. For these reasons and irrespective of the fact that the website was not operated by Pfizer, the 
Commission ruled that it was Pfizer who made sure that the prescription and sale of Viagra via this website was 
promoted.  
In addition, this case underlines another interesting topic: the online or distance selling of medicinal products. 
Pfizer, in cooperation with an e-doctor and internet pharmacy, had set up a system to order Viagra online. From 
the erectieplein.nl website, visitors could log on to the website www.emaildokter.nl and file out an online request 
form for a Viagra prescription. Once the doctor delivered the required prescription, the visitor could purchase 
Pfizer’s erection difficulty product in an online pharmacy.  
According to the Dutch 1963 Act on the distribution of medicinal products, the online distribution of registered 
drugs by e-pharmacies is not strictly forbidden. For this reason, Dutch and European consumers can order drugs 
by telephone, fax or over internet. In the event a prescription is required, it is sufficient that this is sent to the e-
pharmacy, delivering the drugs by post.  
From a European perspective, the situation is more complex. Both the Directive on B2C distance contracts as the 
electronic commerce Directive, applicable to most online activities, grant Member States the right to impose 
restrictions to the online promotion and selling of medical products to safeguard the general interest or public 
health. Article 14 of Directive 97/7 on distance contracts states that Member States may introduce more stringent 
provisions to ensure a higher level of consumer protection, including a ban on the marketing of certain goods or 
services, particularly medicinal products. In addition, the electronic commerce Directive does not encompass 
Member States' legal requirements relating to the delivery or the transport of goods, including the distribution of 
medicinal products.  
In one of the first cases concerning the distance selling of pharmaceutical products, the European Court of Justice 
confirmed this possibility and held that Member States could impose certain restrictions on the cross-border trade 
of medical products. In its judgement of 11 December 2003, the Court held that a national prohibition on the sale 
of medicinal products by mail order is a restriction on the free movement of goods. A distinction is, however, 
made between the sale of prescription and non-prescription medicines. In the event non-prescription medicines 
are sold at a distance, or over the internet, this prohibition is not justified. It is possible that adequate advice and 
information is provided. Furthermore, the European Court stressed that new technologies such as internet, even 
have certain advantages. In contrast, for medicines available on prescription, the Court held that the prohibition 
for e-pharmacies can be justified. The possibility to receive such medicines without any other control could 
increase the risk of prescriptions being abused or incorrectly used. Moreover, the fact that the labelling of a 
medicinal product may be in a different language can have more harmful consequences in the case of 
prescription medicines.  
 
